PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.
Biotech powerhouse Genentech is going all in with Ames, IA-based NewLink Genetics, partnering on an early-stage cancer program which has been billed as an important example of a new class of checkpoint inhibitor. And Genentech says that it plans to build a portfolio of programs pairing this therapeutic with Roche's closely watched PD-L1 drug.
Provectus Biopharmaceuticals, a biotech that has been stung by regulatory setbacks, has recruited INC Research to audit its data on two drug candidates, tasking the CRO with poring over its documents as it moves into late-stage development.
Astellas and CoMentis are calling it quits on their partnership in Alzheimer's disease, as the Japanese drugmaker walks away from a deal valued at up to $760 million.
Sanofi may be trailing in the sprint toward a herpes vaccine, but a new collaboration may give it the boost it needs to stay in the game.
Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But J&J is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too.
Well-funded biotech Moderna Therapeutics has inked a long-term deal with Sweden's Karolinska Institutet to spotlight new applications for the company's messenger RNA technology.
AstraZeneca, two years away from a big relocation to Cambridge, U.K., is broadening its relationship with the local university, signing a slew of new agreements that will bolster its R&D efforts in neuroscience and oncology.
It took a while, but San Diego-based Orexigen has just earned a $70 million milestone from its deal with Takeda on the obesity drug Contrave.
Selecta Biosciences has banked a $20 million-plus round designed to get its lead treatment into the clinic with an eye to providing some basic proof-of-concept data to show that their vaccine particle technology platform will be useful for a full slate of programs.